I-Mab Biopharma of Suzhou has begun treating patients in a China Phase Ib/IIa clinical trial of TJ107 (HyLeukin), a long-acting Interleukin-7 fusion protein, in patients with advanced solid tumors. In 2017, I-Mab in-licensed China rights to HyLeukin from Genexine in a deal worth up to $548 million. I-Mab intends to test HyLeukin, an immune system booster, as a monotherapy for cancer, a treatment for lymphopenia and an adjunct to its cancer immunotherapy candidates.
Source: China Biotoday
